Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of Opdivo and Yervoy, this time in newly diagnosed liver cancer. PD-1 inhibitor ...
It has been announced that following Bristol-Myers Squibb’s (BMS) successful acquisition of Amylin Pharmaceuticals, AstraZeneca (AZ) has made an initial payment of approximately US $3.2 billion, so ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results